October 2024 – Page 17

Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4

7 months ago talkbio0Tagged allergic diseases, Biotechnology, CAMP4, Inflammatory disorder, IPO, Nasdaq, Upstream Bio

Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases

Gritstone Bio Files for Chapter 11 Bankruptcy, Casting Uncertainty Over Cancer Vaccine Development

7 months ago talkbio0Tagged Cancer Vaccines, Chapter 11, Clinical Trials, development aspects, financial restructuring, Gritstone Bio, Immunotherapy, Vaccines

Gritstone Bio, Chapter 11 bankruptcy, cancer vaccine, financial restructuring, clinical trials, immunotherapy, vaccine development.

Eli Lilly Rekindles Partnership with KeyBioscience to Bolster Obesity Drug Pipeline

7 months ago talkbio0Tagged Eli, Eli Lilly, KeyBioscience, Obesity, partnerships, Weight Loss

Eli Lilly, obesity drugs, KeyBioscience, partnerships, weight loss treatments

Immatics Advances Melanoma T-Cell Therapy into Late-Stage Clinical Trials

7 months ago talkbio0Tagged Immatics, Late stage, melanoma, Phase 3 trial, SUPRAME, T-cell therapy

Immatics, melanoma, T-cell therapy, ACTengine IMA203, late-stage clinical trials, SUPRAME Phase 3 trial

FDA Approves Roche’s Itovebi, a PI3K Inhibitor for Advanced Breast Cancer Treatment

7 months ago talkbio0Tagged Approved, HER2-negative, Hormones, Itovebi, Malignant neoplasm of breast, PI3 K inhibitor, PIK3CA Gene Mutation, receptor-positive, Roche (company), United States Food and Drug Administration

Roche, Itovebi, PI3K inhibitor, breast cancer, FDA approval, PIK3CA mutation, hormone receptor-positive, HER2-negative

Glooko Secures $100 Million Funding to Enhance Diabetes Management Platform Under New Leadership

7 months ago talkbio0Tagged Administration occupational activities, Diabetes, Glooko, Healthcare technology, Leadership

Glooko, diabetes management, healthcare technology, funding, new leadership

Ono Pharmaceutical Partners with LigaChem Biosciences for ADC Research and Development

7 months ago talkbio0Tagged Antibody-Drug Conjugates, Biosciences, ConjuAll ADC, Dosage Forms, LCB97, LigaChem, Malignant Neoplasms, Solid Neoplasm, Solid Tumors

Ono Pharmaceutical, LigaChem Biosciences, Antibody-Drug Conjugate (ADC), LCB97, ConjuAll ADC platform, Solid Tumors, Cancer Treatment

CMS Unveils Preliminary List of 101 Generic Drugs for Medicare $2 Out-of-Pocket Plan

7 months ago talkbio0Tagged Adherence (attribute), Drug List, Expenditures, Out-of-Pocket, Health Outcomes, innovation, Medicare, Myasthenic Syndromes, Congenital

Medicare $2 Drug List Model, generic drugs, out-of-pocket costs, medication adherence, health outcomes, CMS Innovation Center

Gritstone Bio Files for Chapter 11 Bankruptcy, Seeks Strategic Alternatives to Preserve Clinical Research

7 months ago talkbio0Tagged Chapter 11, Clinical Research, Communicable Diseases, development aspects, Gritstone Bio, Neoplasms, strategic alternatives, Vaccines

Gritstone Bio, Chapter 11 bankruptcy, strategic alternatives, clinical research, vaccine development, oncology, infectious diseases

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

7 months ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration